NPS MedicineWise Immunoglobulin Consortium
The National Prescribing Service (NPS) MedicineWise was awarded a grant under the Australian Government’s Value in Prescribing program (Immunoglobulin Products stream) for a project which will increase national efforts to improve health outcomes for patients prescribed immunoglobulin products.
The funding has been used by NPS MedicineWise, working with the National Blood Authority and stakeholders (including ASCIA and the Society of Hospital Pharmacists of Australia), to develop and deliver educational resources, tools and interventions to support clinicians in optimising the use of precious immunoglobulin products, as well as to educate consumers on the role of these products.
The substantial annual growth in immunoglobulin use, both in Australia and internationally, together with the relatively high cost of immunoglobulin products and the potential for supply shortages mean that good governance, education and quality improvement are essential to ensure that use remains appropriate, consistent and evidence-based.
This project supports a viable and sustainable immunoglobulin prescribing system by promoting appropriate use of these valuable resources.
Content updated July 2022